Skip to main content

Victor Ambros, Joseph Marr, Stephen DiPalma, James Warren

Premium
Victor Ambros has joined the molecular medicine faculty at the University of Massachusetts Medical School.
 
Ambros, a pioneer in the field of microRNAs, comes to UMMS from Dartmouth Medical School where he served most recently as a professor of genetics. He will officially begin at UMMS in January.
 
Ambros received his undergraduate and graduate degrees at the Massachusetts Institute of Technology, where he also carried out his postdoctoral studies. Before Dartmouth, he was a faculty member at Harvard University.
 

 
Quark Pharmaceuticals has named Joseph Marr as its chief medical officer.
 
Marr previously served as president of BioMed, a consulting firm. At the same time, he was also a general partner at venture capital company Pacific Rim Ventures. He was also formerly vice president of research and development at Ribozyme Pharmaceuticals, which later became Sirna Therapeutics.
 
He holds an MD from the Johns Hopkins University School of Medicine.
 

 
RXi Pharmaceuticals, the RNAi subsidiary of CytRx, has named Stephen DiPalma as its CFO.
 
DiPalma replaces James Warren, who RXi said has left the company to pursue other opportunities.
 
DiPalma was most recently co-founder, president, and CEO of Catalyst Oncology, which recently merged with another firm. Before this, he served as CFO of Milkhaus Laboratory.
 
He holds an MBA from BabsonCollege and a BS in business administration from the University of Massachusetts at Lowell.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.